Skip Main Navigation

Sean Ferree, Ph.D.

Vice President of Diagnostic Development  |  NanoString Technologies

Sean Ferree, Ph.D., is the Vice President of Diagnostic Development at NanoString Technologies, where he manages a team of scientists and engineers developing in vitro diagnostics and companion diagnostics for oncology applications. Dr. Ferree led the team that developed the Prosigna Gene Signature Assay as the first decentralized multi-gene expression signature for prognosis in early-stage breast cancer including submitting and defending the test through regulatory clearance in the US and EU. Dr. Ferree has spent the last 10 years in roles of increasing responsibility at NanoString, first developing the research use-only assay, instruments, and software comprising the nCounter Analysis System, then tailoring the platform for use in multiple genomics research applications, and later developing a second-generation system suitable for diagnostic applications. He received his Ph.D. in Chemical Engineering from the University of California, Berkeley and his B.S. in Chemical Engineering from the University of Colorado, Boulder.